Rabies-Pipeline Review, H1 2015

Rabies-Pipeline Review, H1 2015

  • Products Id :- GMDHC6601IDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rabies-Pipeline Review, H1 2015


Global Markets Direct's, 'Rabies-Pipeline Review, H1 2015', provides an overview of the Rabies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Rabies

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Rabies and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Rabies pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Rabies

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Rabies Overview 9

Therapeutics Development 10

Pipeline Products for Rabies-Overview 10

Pipeline Products for Rabies-Comparative Analysis 11

Rabies-Therapeutics under Development by Companies 12

Rabies-Therapeutics under Investigation by Universities/Institutes 14

Rabies-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Rabies-Products under Development by Companies 18

Rabies-Products under Investigation by Universities/Institutes 20

Rabies-Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co., Ltd 21

Celltrion, Inc. 22

CureVac GmbH 23

Humabs BioMed SA 24

Kaketsuken K.K. 25

Kamada Ltd. 26

Medicago Inc. 27

Molecular Targeting Technologies, Inc. 28

NanoViricides, Inc. 29

Novavax, Inc. 30

PaxVax 31

Prosetta Antiviral Inc. 32

Sanofi 33

Serum Institute of India Limited 34

Sinovac Biotech Ltd. 35

Trellis Bioscience, Inc. 36

VBI Vaccines Inc. 37

Zydus Cadila Healthcare Limited 38

Rabies-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 42

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

CTP-19-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

CV-7201-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CV-8102-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ebola + rabies vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

human rabies vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

KD-357-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Monoclonal Antibodies for Rabies-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Monoclonal Antibodies to Inhibit Glycoprotein for Rabies-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Monoclonal Antibody for Rabies-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

PAV-866-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

RabiCide-I-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

rabies immune globulin (human)-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

rabies vaccine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

rabies vaccine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

rabies vaccine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

rabies vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

rabies vaccine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

rabies vaccine-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

rabies virus like particle vaccine-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Rabimabs-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

SII RMab-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

SO-57-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

SOJB-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

VerorabVax-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Rabies-Recent Pipeline Updates 73

Rabies-Dormant Projects 75

Rabies-Product Development Milestones 76

Featured News & Press Releases 76

Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 76

Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 76

Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 77

May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 77

Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 77

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Rabies, H1 2015 10

Number of Products under Development for Rabies-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Rabies-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 21

Rabies-Pipeline by Celltrion, Inc., H1 2015 22

Rabies-Pipeline by CureVac GmbH, H1 2015 23

Rabies-Pipeline by Humabs BioMed SA, H1 2015 24

Rabies-Pipeline by Kaketsuken K.K., H1 2015 25

Rabies-Pipeline by Kamada Ltd., H1 2015 26

Rabies-Pipeline by Medicago Inc., H1 2015 27

Rabies-Pipeline by Molecular Targeting Technologies, Inc., H1 2015 28

Rabies-Pipeline by NanoViricides, Inc., H1 2015 29

Rabies-Pipeline by Novavax, Inc., H1 2015 30

Rabies-Pipeline by PaxVax, H1 2015 31

Rabies-Pipeline by Prosetta Antiviral Inc., H1 2015 32

Rabies-Pipeline by Sanofi, H1 2015 33

Rabies-Pipeline by Serum Institute of India Limited, H1 2015 34

Rabies-Pipeline by Sinovac Biotech Ltd., H1 2015 35

Rabies-Pipeline by Trellis Bioscience, Inc., H1 2015 36

Rabies-Pipeline by VBI Vaccines Inc., H1 2015 37

Rabies-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Assessment by Combination Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Rabies Therapeutics-Recent Pipeline Updates, H1 2015 73

Rabies-Dormant Projects, H1 2015 75

List of Figures

Number of Products under Development for Rabies, H1 2015 10

Number of Products under Development for Rabies-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Beijing Minhai Biotechnology Co., Ltd

Celltrion, Inc.

CureVac GmbH

Humabs BioMed SA

Kaketsuken K.K.

Kamada Ltd.

Medicago Inc.

Molecular Targeting Technologies, Inc.

NanoViricides, Inc.

Novavax, Inc.


Prosetta Antiviral Inc.


Serum Institute of India Limited

Sinovac Biotech Ltd.

Trellis Bioscience, Inc.

VBI Vaccines Inc.

Zydus Cadila Healthcare Limited

Rabies Therapeutic Products under Development, Key Players in Rabies Therapeutics, Rabies Pipeline Overview, Rabies Pipeline, Rabies Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com